EVOCLIN
Clinical safety rating: caution
Comprehensive clinical and safety monograph for EVOCLIN (EVOCLIN).
Clindamycin is a lincosamide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the ribosome, blocking peptide bond formation.
| Metabolism | Primarily hepatic metabolism via CYP3A4 to active and inactive metabolites; also undergoes some renal clearance. |
| Excretion | Primarily hepatic metabolism; renal excretion of unchanged drug accounts for approximately 10% of elimination. Biliary/fecal excretion accounts for <2%. |
| Half-life | Terminal elimination half-life is approximately 15 hours (range 10-25 hours) following topical application, allowing for twice-daily dosing. |
| Protein binding | Approximately 90-95% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Volume of distribution (Vd) is approximately 1.0-1.5 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Systemic bioavailability following topical application is low, approximately 1-2%, due to minimal percutaneous absorption. |
| Onset of Action | Clinical effect (reduction in inflammatory lesions) typically observed within 2-4 weeks of twice-daily application. |
| Duration of Action | Duration of action persists for the dosing interval (12 hours) with sustained effects over the course of therapy; maximal effect seen at 12 weeks. |
| Molecular Weight | 424.98 |
EVOCLIN (clindamycin phosphate) foam 1%: Apply once daily to affected area(s) of the face, shoulders, chest, and back.
| Dosage form | AEROSOL, FOAM |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | For pediatric patients 12 years and older: same as adult dosing. Safety and efficacy in children under 12 years have not been established. |
| Geriatric use | No specific dose adjustment; use caution due to potential for age-related hepatic or renal dysfunction. |
| 1st trimester | Safety not established; avoid use during first trimester unless benefit outweighs risk. Animal studies show delayed skeletal development at high doses. |
| 2nd trimester | Use only if clearly needed; no adequate human studies. Potential risk of fetal ototoxicity and nephrotoxicity. |
| 3rd trimester | Contraindicated in third trimester due to risk of infantile hypertrophic pyloric stenosis after exposure to topical clindamycin. |
Clinical note
Comprehensive clinical and safety monograph for EVOCLIN (EVOCLIN).
| Placental transfer | Clindamycin crosses the placenta; cord blood levels are approximately 50% of maternal serum levels after systemic administration. |
| Breastfeeding | Clindamycin is excreted in human milk after topical application, though amounts are low. However, direct infant exposure via breastfeeding is possible. Monitor infant for gastrointestinal disturbances (e.g., diarrhea, candidiasis) and potential antibiotic resistance. |
■ FDA Black Box Warning
Clindamycin can cause severe and sometimes fatal colitis, including pseudomembranous colitis, due to Clostridium difficile overgrowth.
| Serious Effects |
History of pseudomembranous colitisHypersensitivity to clindamycin or lincomycinThird trimester of pregnancyPreterm infants (age < 6 months, due to benzyl alcohol content)
| Precautions | Risk of Clostridium difficile-associated diarrhea (CDAD); may cause severe hypersensitivity reactions; use with caution in patients with gastrointestinal disease, hepatic impairment, or renal impairment; prolonged use may result in superinfection. |
| Food/Dietary | None known; take with or without food. Avoid alcohol consumption if using other medications that interact with clindamycin (e.g., erythromycin). |
Loading safety data…
| Lactation Rating | L2 (limited data - probably compatible) |
| Teratogenic Risk | Clindamycin (active ingredient) is Pregnancy Category B; animal studies show no fetal harm, but no adequate human studies. First trimester: minimal risk, but use only if clearly needed. Second/third trimester: no known teratogenic effects; avoid in preterm labor due to rare risk of pseudomembranous colitis in neonates. |
| Fetal Monitoring | Monitor maternal signs of pseudomembranous colitis (diarrhea, abdominal cramps). No specific fetal monitoring required; standard prenatal care. |
| Fertility Effects | No known adverse effects on fertility in animal studies. Clinical data insufficient. |
| Clinical Pearls | EVOCLIN (clindamycin phosphate) foam is for topical use only. Avoid contact with eyes and mucous membranes. Apply to affected area, not broken skin. Not for oral or ophthalmic use. Can be used in combination with benzoyl peroxide or retinoids. May cause skin irritation; if severe, discontinue. Store at room temperature; do not freeze. |
| Patient Advice | Use exactly as prescribed; do not use more or less than directed. · Apply a thin layer to the affected area once daily (usually in the morning). · Avoid contact with eyes, mouth, and broken skin. · Do not shower or swim immediately after application; wait at least 1 hour. · If irritation occurs, inform your healthcare provider. · Do not use with other topical antibiotics without consulting your doctor. · Wash hands before and after application. · Keep away from heat, flame, or smoking until foam has dried. |